Combination Therapy with Ibrexafungerp (Formerly SCY-078), a First-in-Class Triterpenoid Inhibitor of (1→3)-β- d -Glucan Synthesis, and Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Ibrexafungerp (formerly SCY-078) is a semisynthetic triterpenoid and potent (1→3)-β- d -glucan synthase inhibitor. We investigated the in vitro activity, pharmacokinetics, and in vivo efficacy of ibrexafungerp (SCY) alone and in combination with antimold triazole isavuconazole (ISA) against invasive pulmonary aspergillosis (IPA). The combination of ibrexafungerp and isavuconazole in in vitro studies resulted in additive and synergistic interactions against Aspergillus spp.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kontoyiannis, D. P., Marr, K. A., Park, B. J., Alexander, B. D., Anaissie, E. J., Walsh, T. J., Ito, J., Andes, D. R., Baddley, J. W., Brown, J. M., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/651263 · Cited by 1,456
Self-citationRat monoclonal antibodies against Aspergillus galactomannan
Stynen, D., Sarfati, J., Goris, A., Prévost, M. C., Lesourd, M., Kamphuis, H., Darras, V, & Latgé, J. P. (1992) · Infection and Immunity · doi:10.1128/iai.60.6.2237-2245.1992 · Cited by 267 · cited 1×
“Galactomannan antigen, expressed as galactomannan index (GMI), was determined in serial serum samples and BAL fluid obtained postmortem by one-stage immunoenzymatic sandwich microplate assay method (30) (Platelia Aspergillus enzyme immunoassay [EIA]; Bio-Rad, Marnes la Coquette, France) according to the manufacturer’s…”
MethodPfaller, M. A., Messer, S. A., Motyl, M. R., Jones, R. N., & Castanheira, M. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01588-12 · Cited by 98
Pfaller, M. A., Messer, S. A., Rhomberg, P. R., Borroto-Esoda, K., & Castanheira, M. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00161-17 · Cited by 84
Self-citationGhannoum, M., Long, L., Larkin, E. L., Isham, N., Sherif, R., Borroto-Esoda, K., Barat, S., & Angulo, D. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00244-18 · Cited by 80 · cited 2×
“Even though there is some data on its activity in combination with antimold triazoles in vitro, little is known about ibrexafungerp efficacy in combination treatment against IPA in vivo (11, 12).”
BackgroundMethodSelf-citationSchell, W. A., Jones, A. M., Borroto-Esoda, K., & Alexander, B. D. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01102-17 · Cited by 66
Self-citationWiederhold, N. P., Najvar, L. K., Jaramillo, R., Olivo, M., Pizzini, J., Catano, G., & Patterson, T. F. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx422 · Cited by 43
Katragkou, A., McCarthy, M., Meletiadis, J., Petraitis, V., Moradi, P. W., Strauss, G. E., Fouant, M. M., Kovanda, L. L., Petraitiene, R., Roilides, E., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03261-14 · Cited by 42 · cited 1×
“fumigatus in triplicate with an in vitro broth microdilution checkerboard assay in 96-well flat bottom microtitration plates (Corning Incorporated, Corning, NY) based on the CLSI M-38A method as previously described (25).”
MethodSelf-citation
Research works printed but not linked: 22
- 10.1136/thoraxjnl-2014-206291 · DOI · Paper page
- 10.1080/13693780902718339 · DOI
- 10.1097/MPH.0b013e3181acd956 · DOI
- 10.1053/j.seminhematol.2009.03.008 · DOI
- 10.1128/AAC.01510-19 · DOI · Paper page
- 10.1080/14787210.2018.1536546 · DOI
- 10.1128/AAC.02145-13 · DOI · Paper page
- 10.1093/jac/dkx033 · DOI
- 10.1093/jac/dks466 · DOI · Paper page
- 10.1128/AAC.04445-14 · DOI · Paper page
- 10.1128/AAC.02068-16 · DOI · Paper page
- 10.1128/AAC.00585-18 · DOI
- 10.1093/cid/cix198 · DOI
- 10.1111/myc.12769 · DOI
- Petraitis V, Kavaliauskas P, Planciuniene R, Virgailis M, Petraitiene R, Barat S, Borroto-Esoda K, Angulo D, Walsh TJ. 2018. In vitro activity of SCY-078 in combination with isavuconazole or amphotericin B against medically important moulds, abstr 498. ASM Microbe 2018. ASM, Atlanta, GA.
- 10.1086/375420 · DOI · Paper page
- Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved Standard—2nd ed. CLSI document M38-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
- 10.1128/aac.47.1.106-117.2003 · DOI · Paper page
- National Research Council. 2011. Guide for the care and use of laboratory animals, 8th ed. National Academies Press, Washington, DC.
- Walsh TJ, Bacher J, Pizzo PA. 1988. Chronic silastic central venous catheterization for induction, maintenance and support of persistent granulocytopenia in rabbits. Lab Anim Sci 38:467–471.
- 10.1128/AAC.45.3.857-869.2001 · DOI · Paper page
- 10.1128/AAC.00674-08 · DOI
Cited by
The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin
Hoenigl, M., Sprute, R., Egger, M., Arastehfar, A., Cornely, O. A., Krause, R., Lass-Flörl, C., Prattes, J., Spec, A., Thompson, G. R., et al. (2021) · Drugs · doi:10.1007/s40265-021-01611-0 · Cited by 467
“5 mg/ kg bodyweight daily) plus isavuconazole (40 mg/kg bodyweight daily) not only reduced pulmonary fungal burden in a neutropenic rabbit model but also prolonged survival [146].”
BackgroundIbrexafungerp: A First-in-Class Oral Triterpenoid Glucan Synthase Inhibitor
Jallow, S., & Govender, N. P. (2021) · Journal of Fungi · doi:10.3390/jof7030163 · Cited by 129
New antifungal strategies: Drug combination and co-delivery
Zhu, P., Li, Y., Guo, T., Liu, S., Tancer, R. J., Hu, C., Zhao, C., Xue, C., & Liao, G. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114874 · Cited by 63
Pharmacokinetics and Pharmacodynamics of Ibrexafungerp
McCarthy, M. W. (2022) · Drugs in R&D · doi:10.1007/s40268-021-00376-x · Cited by 28
Metadata
- Authors
- Petraitis, V., Petraitiene, R., Katragkou, A., Maung, B. B. W., Naing, E., Kavaliauskas, P., Barat, S., Borroto-Esoda, K., Azie, N., Angulo, D., & Walsh, T. J.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2020-05-21
- Volume
- 64
- Issue
- 6
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W3011590223
- Cited by
- 47
- References
- 8
- FWCI
- 0.69
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Funders
- Scynexis, Inc.
- Save Our Sick Kids Foundation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Combination Therapy with Ibrexafungerp (Formerly SCY-078), a First-in-Class Triterpenoid Inhibitor of (1→3)-β- d -Glucan Synthesis, and Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis. https://app.cochat.ai/papers/10.1128/aac.02429-19
- The paper
- Petraitis, V., Petraitiene, R., Katragkou, A., Maung, B. B. W., Naing, E., Kavaliauskas, P., Barat, S., Borroto-Esoda, K., Azie, N., Angulo, D., & Walsh, T. J. (2020). Combination Therapy with Ibrexafungerp (Formerly SCY-078), a First-in-Class Triterpenoid Inhibitor of (1→3)-β- d -Glucan Synthesis, and Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.02429-19
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.